Silence Therapeutics plc(SLN)

$13.42—Stale · unknown old

Chart

Silence Therapeutics plc(SLN)

NASDAQ • Last print unknown ago

$13.42—Stale · unknown old

Chart Studio

SLN(SLN)

SLN

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.12

Nov 5, 2026 · Reports before open

Revenue Estimate

$124,217

Analyst Sentiment

Wall St. Consensus

Buy

5 analysts·Limited coverage

Score

4 Buy (80%)0 Hold (0%)1 Sell (20%)

Rating Breakdown

Strong Buy

00%

Buy

480%

Hold

00%

Sell

120%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$49.00

+265.1%

Consensus

$55.00

+309.8%

Bull

$67.00

+399.3%

12-Month Target Range5 analysts

$49.00$55.00$67.00

Current $13.42Consensus

Current Price

$13.42

Upside to Consensus

$41.58

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+155.56%

EPS—

FY2028

Rev-48.38%

EPS—

FY2029

Rev+21.84%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$528,814	$1M	$697,651	$850,000	$101M
Low	$515,916	$184,665	$200,400	$244,162	$29M
High	$541,711	$3M	$1M	$1M	$175M
EBITDA Avg	$-7M	$-9M	$-10M	$-9M	$-6M
Low	$-10M	$-17M	$-20M	$-19M	$-12M
High	$-2M	$-2M	$-448,286	$-449,570	$839,658
EBIT Avg	$-8M	$-9M	$-10M	$-10M	$-7M
Low	$-11M	$-18M	$-20M	$-19M	$-13M
High	$-3M	$-3M	$-756,155	$-705,384	$-491,524
Net Income Avg	$-8M	$-9M	$-10M	$-10M	$-7M
Low	$-11M	$-18M	$-21M	$-19M	$-13M
High	$-3M	$-3M	$-767,489	$-716,718	$-502,858
EPS Avg	$-0.49	$-0.58	$-0.66	$-0.62	$-0.43
Low	$-0.70	$-1.12	$-1.30	$-1.22	$-0.85
High	$-0.17	$-0.17	$-0.05	$-0.05	$-0.03
Analysts (Rev / EPS)	5 / 3	4 / 3	1 / 1	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$124,217	$102,683	$1M	$1M	$2M	$2M	$164,100	$155,900
Low	$7,235	$5,981	$68,098	$83,131	$99,662	$99,877	$9,559	$9,081
High	$241,198	$199,384	$2M	$3M	$3M	$3M	$318,640	$302,718
EBITDA Avg	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M	$-1M	$-1M
Low	$-2M	$-2M	$-5M	$-5M	$-4M	$-5M	$-3M	$-3M
High	$-2M	$-1M	$596,185	$656,032	$571,967	$638,721	$458,104	$460,327
EBIT Avg	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M
Low	$-2M	$-2M	$-5M	$-5M	$-4M	$-5M	$-3M	$-3M
High	$-2M	$-2M	$499,562	$560,245	$476,180	$542,923	$366,637	$372,997
Net Income Avg	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M
Low	$-2M	$-2M	$-5M	$-5M	$-4M	$-5M	$-3M	$-3M
High	$-2M	$-2M	$471,531	$528,809	$449,461	$512,459	$346,065	$352,068
EPS Avg	$-0.12	$-0.12	$-0.13	$-0.15	$-0.13	$-0.15	$-0.10	$-0.10
Low	$-0.12	$-0.13	$-0.30	$-0.33	$-0.28	$-0.32	$-0.22	$-0.22
High	$-0.11	$-0.10	$0.03	$0.03	$0.03	$0.03	$0.02	$0.02
Analysts (Rev / EPS)	4 / 3	6 / 2	3 / 1	3 / 1	3 / 1	3 / 1	4 / 1	4 / 1

Earnings Surprises

Recent Analyst Actions

Jun 28, 2024Chardan Capital

Silence Therapeutics price target raised to $55 from $42 at Chardan

Target:$55.00

+189.5%from $19.00

Jun 28, 2024Morgan Stanley

Silence Therapeutics price target raised to $49 from $45 at Morgan Stanley

Target:$49.00

+157.9%from $19.00

Mar 13, 2024BMO Capital

BMO Capital Reiterates Silence Therapeutics (SLN) as Top Pick, 'buy the dip'

Target:$67.00

+161.6%from $25.61

Dec 9, 2022Morgan Stanley

Morgan Stanley Initiates Coverage On Silence Therapeutics with Equal-Weight Rating, Announces Price Target of $18

Target:$18.00

+18.2%from $15.23

Nov 17, 2022Chardan Capital

Chardan Capital Maintains Buy on Silence Therapeutics, Lowers Price Target to $29

Target:$29.00

+119.5%from $13.21

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance